Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
'longboarder7892', yep, we are getting close. It going to get exciting here soon.
Go PMCB!
Something is not right here!
'$Pistol Pete$', Great, hopefully they will answer your concerns and questions.
'1234jklm', I do not think a company can do that due to SEC regulations.
'$Pistol Pete$', I honestly have no answer to your question.
'$Pistol Pete$', I truly cannot answer your question, because I do not know. Email them and ask them why are they illegal nominate themselves as BOD and benefit almost $10M dollars in 4 years without shareholders voting.
'1234jklm', Agree the salaries may be a bit high , but how else is a start-up company to get the $$$ needed.
If they borrow $$$, being a company with one possible product at the moment, the interest rate will be very high. They have no income stream yet.
At least this company is not over their head in debt. If is was, I would not be a shareholder here.
The company will be selling shares at a much higher price when the IND is submitted. Watch and see!
'$Pistol Pete$', this is MOHO, they will be selling additional shares at a much higher when the IND is filed. I myself would not sell my shares this close to the IND submission.
I look at all the high class physicians involved for this being a scam. PMCB is not a scam.
'1234jklm', Look at the daily volume tells all. If the company was selling shares right now, the volume would be much higher. Common sense.
Something seems fishy to me here on this board, with $Pistol Pete$ and other long term shareholders all of a sudden being so negative on the company. Are they using reverse psychology to get shares on the cheap???
Meaning of reverse psychology - the principle or practice of subtly encouraging a behavior or belief by advocating its opposite.
Media Release: InfiniGold to launch the Perth Mint Gold Token
Friday 11 October 2019
MEDIA RELEASE
InfiniGold to launch the Perth Mint Gold Token
The Perth Mint Gold Token (PMGT) will be the first digital gold token on a public blockchain backed by government guaranteed gold.
Sydney, Australia - Leading precious metals digitisation company, InfiniGold has today announced the launch of the Perth Mint Gold Token (PMGT), a digital token backed 1:1 by GoldPass certificates issued by The Perth Mint, the world’s largest refiner of newly mined gold which is guaranteed by the highly rated sovereign entity, the Government of Western Australia.
PMGT is digitised gold that allows users to conveniently acquire and have entitlement over government guaranteed physical gold stored at The Perth Mint in a trusted and cost-effective way. It offers institutional investors a competitive alternative to traditional gold products such as gold ETFs, with the additional benefits of real-time trading and settlement enabled by blockchain technology.
Digitisation of The Perth Mint’s inventory began in 2018 when GoldPass was launched, where, via a mobile app, investors can instantly and securely buy, sell and transfer physical gold via digital certificates. Each certificate is 100% backed by physical Perth Mint gold stored in its network of central bank grade vaults, with every ounce of gold held in storage guaranteed by the Government of Western Australia.
PMGT, issued by InfiniGold as an ERC-20 compatible asset-backed token, is bringing GoldPass and the physical Perth Mint gold that backs each certificate to the public blockchain. With PMGT, InfiniGold and The Perth Mint are leading the field to transform gold into a multi-billion dollar digital asset.
The real-time liquidity of PMGT is provided by market makers and enabled via The Perth Mint GoldPass platform where users can sell back to The Perth Mint, or take delivery of their holdings by exchanging their GoldPass certificates for a range of the Mint’s gold products, including LBMA London Good Delivery (LGD) bars. Subject to final regulatory consultation, this will make PMGT directly tradable against traditional gold products, including gold ETFs, CME gold futures, and physical XAU.
PMGT provides a unique alternative to USD-backed stablecoins which have attracted inflows of US$2.3bn year-to-date in 2019 and average daily trading volumes in excess of US$15bn. PMGT offers owners superior transparency, credit quality, risk diversification and hedging against market volatility as the token represents physical gold, which has historically been much more stable and a well-understood store of value.
Andreas Ruf, CEO of InfiniGold said: “We’ve been looking forward to unveiling PMGT, an exciting result of our collaboration with The Perth Mint - the preeminent precious metals institution in the world. With The Perth Mint as custodian of the underlying physical gold that backs PMGT, buyers will be able to access a secure and reliable token representing the strongest asset class to date – gold.
“We’re delighted to be working with InfiniGold and offer safe storage for the physical gold we will supply and hold, as our role as custodian through GoldPass certificates,” said Richard Hayes, Chief Executive Officer of The Perth Mint.
“The digitisation of gold via a public ledger is a natural progression for the global commodity markets. It will promote gold as a mainstream asset, enhance its accessibility, and offer greater liquidity, transparency and auditability of the real assets backing this type of digital token,” concluded Hayes.
Ernst and Young worked with InfiniGold to perform a findings and recommendations report on the design effectiveness of the procedures and controls over the PMGT platform. Ruf said: “We chose to proactively work with EY to implement strong procedures and controls around the PMGT platform well before go-live as we know effective management of digital assets risks is critical to our investors and we felt EY were best placed to assist us.”
Jon Deane, a former Managing Director at JP Morgan and now CEO of TCM Capital, which has been advising the project, said: “The involvement of The Perth Mint as the largest refinery in the world and a leading exporter of gold, ensures that the product offers both the scalability and credibility that the market clearly needs.” The Chairman of TCM Capital, Steve Bellotti, went on to say, ”InfiniGold’s PMGT is perfectly positioned, via the blockchain, to complement the current institutional gold market.”
ENDS
Media contact for InfiniGold:
Frances Wells, Cryptoland PR
US: 866-586-5603
UK: +44 020 3908 5686
E: frances@cryptolandpr.com
ABOUT INFINIGOLD
InfiniGold is a leading precious metals digitisation company that has developed a platform for the digitisation of gold and other precious metals. A spinout from Rozetta Ventures and part of the RoZetta Group (rozetta.com.au, formerly Capital Markets CRC), the technology underpinning InfiniGold’s digital gold certificates is co-developed with other Rozetta Institute companies. It is also used to issue electronic cash and for the trading, clearing and settlement of unlisted securities. Th e core InfiniGold team previously developed SMARTS, the global leading market surveillance business that was acquired by NASDAQ in 2010. For more information please visit: pmgt.io.
ABOUT THE PERTH MINT
The Perth Mint is the trading name of Gold Corporation, an entity wholly owned and guaranteed by the Government of Western Australia which holds a long-term AA+ credit rating (S&P).
The Perth Mint is Australia’s only fully integrated precious metals refining, minting and depository enterprise. Operating the largest refinery of newly mined gold in the world, the Mint processes more than 90% of Australia’s primary gold production, which equates to over 10% of global output. With a capacity to process in excess of 800 tonnes of gold annually, The Perth Mint refinery belongs to a select group which is accredited by the five major gold exchanges, being the London Bullion Market Association (LBMA), the New York Commodities Exchange (COMEX), the Shanghai Gold Exchange (SGE), the Tokyo Commodities Exchange (TOCOM) and the Dubai Multi Commodities Centre (DMCC).
The Perth Mint also operates the most extensive network of central bank grade vaulting facilities in the southern hemisphere, where it safeguards precious metals worth more than US$3bn dollars on behalf of investors throughout the world. As one of Western Australia’s top three exporters, The Perth Mint consistently delivers in excess of US$16bn worth of precious metal bars and coins to investors in more than 130 countries each year. For more information please visit: perthmint.com
ABOUT TCM CAPITAL AM
TCM Capital AM Pty Ltd is the Advisor to the PMGT project. TCM Capital is an emerging neo investment bank with an internationally experienced team including former leaders of top-tier global investment banks, trading operations and asset managers. With a focus on emerging technologies across its Origination & Advisory, Global Markets and Asset Management operations, TCM is facilitating the digitisation of current assets and securities, as well as introducing new assets and asset classes to traditional market participants. For more information please visit: tokencapitalmanagementltd.com
https://www.perthmint.com/media-infinigold-pmgt.aspx
https://www.google.com/search?rlz=1CBACBD_enUS843&sxsrf=ACYBGNT607IeR4QfJHv5we0qmWLejTYIIw%3A1571979963458&source=hp&ei=u4KyXb-TGdKUsgX3rp7YBQ&q=perth+mint+gold+token&oq=Perth+Mint+Gold+Token&gs_l=psy-ab.1.0.0l3.3010.3010..7337...0.0..0.117.117.0j1......0....2j1..gws-wiz.jnAlXXN3v74
'$Pistol Pete$', Thanks, I'm not going anywhere. I'm here until the end!
I'm really amazed to see so many here wanting this company to fail. I just don't get it. If I had a family member with pancreatic cancer I would be hopeful that PMCB succeeds. MOHO though!
I will be anxious in listening to the CC next week. I'm pleased that the company will be providing a recording of the call next week. Not selling any of my shares here, I may even add.
The call is scheduled for Friday, September 20, 2019, commencing at 4:00 p.m. Eastern Daylight Time. The telephone number for the call is (515) 604-9056. The access code for the call is 195-864.
https://ir.pharmacytebiotech.com/press-releases/detail/208
'EDavis8', Thanks for the update, much appreciated.
'mwebb1514', thanks so much for the update on today's shareholder meeting, so much appreciated here. I wish you a good evening!
Me too!
'lucmariepierre', it could, if the company plays it's cards right. No RS, but do a share repurchase down here would go a long ways in increasing the share price. This would instill investor confidence going forward.
That quote caught my eye too.
This explains all about the preferred stock offering. Taken from page 4 of the proxy statement.
https://content.equisolve.net/_76803de5f2d1d72f01142193aef36499/pharmacytebiotech/db/191/429/pdf/attachment+1.pdf
ITEM 1 — Approval of Articles Amendment to Provide the Board the Power to Designate the Rights and Preferences
of PharmaCyte’s Preferred Stock
Authorization of “Blank Check” Preferred Stock
On August 10, 2019, our Board unanimously approved the Articles Amendment to provide our Board the power to
designate the rights and preferences of our preferred stock. Our current Articles authorize 10,000,000 shares of preferred stock,
such preferred stock is not “blank check” preferred stock. The term “blank check” refers to preferred stock, the creation and
issuance of which is authorized in advance by our stockholders and the terms, rights and features of which are determined by our
Board upon issuance. The authorization of such “blank check” preferred stock permits our Board of to authorize and issue
preferred stock from time to time in one or more series without seeking further action or vote of our stockholders. The Articles
Amendment will not increase or decrease the number of authorized shares of preferred stock. Rather, the Articles Amendment
makes the authorized preferred shares blank check preferred shares.
If the Articles Amendment is approved, the Board will have the power to authorize and issue preferred stock from time
to time in one or more series without seeking further action or vote of our stockholders, and the Board will designate the rights
and preferences of any such series. Subject to the provisions of the Articles Amendment and the limitations prescribed by law,
our Board would be expressly authorized, at its discretion, to adopt resolutions to issue shares, to fix the number of shares and to
change the number of shares constituting any series and to provide for or change the voting powers, designations, preferences
and relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, including dividend
rights (including whether the dividends are cumulative), dividend rates, terms of redemption (including sinking fund provisions),
redemption prices, conversion rights and liquidation preferences of the shares constituting any series of the preferred stock, in
each case without any further action or vote by our stockholders. Our Board would be required to make any determination to
issue shares of preferred stock based on its judgment as to what is in the best interests of PharmaCyte and our stockholders.
The Board believes that the authorization of the blank check preferred stock will provide PharmaCyte with increased
financial flexibility in meeting future capital requirements. It will allow preferred stock to be available for issuance from time to
time and with such features as determined by our Board for any proper corporate purpose. In addition, if the Articles Amendment
is approved by stockholders, following the filing of the Articles Amendment with the Secretary of State of Nevada, the Board
intends to designate a series of preferred stock with supermajority voting power (“New Series”) and to issue one or more shares
of such New Series to an officer of PharmaCyte. It is expected that such officer will vote his shares of the New Series to approve
a certificate of amendment to the Articles that will have the effect of increasing the authorized shares of PharmaCyte’s Common
Stock. The Board believes that additional authorized shares of Common Stock will provide PharmaCyte with increased financial
flexibility in meeting future capital requirements. However, PharmaCyte has no present plans or commitments for the issuance
or use of the additional shares of Common Stock that may be authorized.
If the Articles Amendment is approved, it will become effective upon the filing of the Articles Amendment with the
Secretary of State of the State of Nevada.
Effect of Proposal 1 on Current Stockholders
The issuance by PharmaCyte of preferred stock could dilute both the equity interests and the earnings per share of
existing holders of our Common Stock. Such dilution may be substantial, depending upon the number of shares issued. The
newly authorized shares of preferred stock could also have voting rights superior to our Common Stock, and therefore would
have a dilutive effect on the voting power of our existing stockholders.
Any issuance of preferred stock with voting rights could, under certain circumstances, have the effect of delaying or
preventing a change in control of PharmaCyte by increasing the number of outstanding shares entitled to vote and by increasing
the number of votes required to approve a change in control of PharmaCyte. Shares of voting or convertible preferred stock could
be issued, or rights to purchase such shares could be issued, to render more difficult or discourage an attempt to obtain control
of PharmaCyte by means of a tender offer, proxy contest, merger or otherwise. The ability of our Board to issue such shares of
preferred stock, with the rights and preferences it deems advisable, could discourage an attempt by a party to acquire control of
PharmaCyte by tender offer or other means.
Vote Required
Proposal 1 will be approved if the votes cast by the holders of the shares represented at the meeting and entitled to vote
exceed the votes cast opposing the action (with “abstentions” and “broker non-votes” not counted as a vote cast with respect to
that matter). This means that the number of shares voted “FOR” Proposal 1 must exceed the number of shares voted “Against”
Proposal 1.
The stock will not trade at par, which is $0.001 a share. Since the company does not know the actual price the shares may be sold for, they use the par amount. It would be BK if the shares traded at par = $0.001 a share. Not going to trade at par anytime soon.
'Disquisition', your post does not include the conversion price @ $0.001. Refer below from the 10-g. Page 38.
https://ih.advfn.com/stock-market/AMEX/camber-energy-CEI/stock-news/80541878/quarterly-report-10-q
As of August 14, 2019, we had 250 million authorized shares of common stock and 26,128,200 shares of common stock issued and outstanding. As of August 14, 2019, the Series C Holders are still due approximately 56 billion shares of common stock upon conversion of the outstanding shares of Series C Preferred Stock, which have a current conversion price of $0.001 per share, and an additional 28,231,700 shares in connection with shares of Series C Preferred Stock previously converted which are held in abeyance subject to such holders’ 9.99% ownership limitations). Such number of shares exceeds by 225 times the number of shares of common stock we have authorized for future issuance. As such, the holders of our Series C Preferred Stock have the ability to convert the shares of Series C Preferred Stock into a number of shares of common stock which would prevent us from issuing any other shares of common stock for compensation, future acquisitions or other matters. In the event the limit of our authorized number of shares of common stock are reached we would need to take action to increase such number of authorized but unissued shares of common stock, which would only provide the Series C Preferred Stock holders with futher ability to convert such Series C Preferred Stock into common stock and as described in the risk factors below, create further dilution to existing shareholders and reductions in the trading price of our common stock.
-------------------------------------------------------------------
'Disquisition' your misleading and false post below. You left out the conversion price.
Straight from the 10-Q:
“As of August 14, 2019, the Series C Holders are still due approximately 56,342,906,515 shares of common stock upon conversion of the outstanding shares of Series C Preferred Stock (significantly more than the 250 million shares we have authorized)”
Here are the last trades.. Some are large, especially the 588,888 volume trade @ 15:54:10 for 0.0391.
Time Price Volume Market
15:57:30 0.0391 500 OTO
15:57:01 0.0378 200 OTO
15:54:44 0.03765 4450 OTO
15:54:10 0.0391 588888 OTO
15:54:07 0.0376 1500 OTO
15:54:07 0.039 100000 OTO
15:53:58 0.0389 77200 OTO
15:53:51 0.038 158675 OTO
15:52:26 0.037 69500 OTO
15:52:16 0.037 10000 OTO
15:52:12 0.037 20500 OTO
15:42:45 0.0353 5000 OTO
15:28:04 0.03615 5000 OTO
15:26:26 0.0353 10000 OTO
15:15:30 0.037 15000 OTO
15:06:41 0.0369 500 OTO
15:02:53 0.0353 65056 OTO
15:02:53 0.0353 63400 OTO
15:02:49 0.0354 10000 OTO
15:02:49 0.036 7944 OTO
15:02:48 0.0355 25800 OTO
15:02:48 0.0355 17000 OTO
15:02:36 0.0355 12900 OTO
15:02:31 0.0355 12900 OTO
15:02:25 0.036775 3000 OTO
15:02:25 0.036 50000 OTO
15:02:16 0.036 53296 OTO
15:02:14 0.036 6704 OTO
15:02:10 0.036 75000 OTO
15:01:35 0.036 25000 OTO
https://quotes.freerealtime.com/quotes/PMCB/Time&Sales
Agree, something drastic is happening here soon!
Next several weeks could get very interesting indeed. GLTA PMCB'rs
Agree!
Yep, I like your thinking here. When I saw the late filing this evening, I thought hmmmm!!!
They may have not wanted to disclose these events in the filing that is required by law if they are in talks with a buyout, merger or partner.
Exactly what I'm thinking here. Today's late filing may be telling us something here. The company has never been late on their SEC filings. The company has been awfully quiet lately. Something may be cooking here, we will see!
If the company knows that it is in merger or buyout talks, there may be no need to spend the extra $$$ to submit the SEC filing. We will see!
SEC filing may be late due to a merger or a buyout offer. The company has been awfully quiet lately. We will see!
From Facebook today
Austrianova
4 hrs ·
Austrianova CTO and Chairman, Walter H. Gunzburg, giving a presentation to a potential partner today.
https://scontent-ort2-1.xx.fbcdn.net/v/t1.0-9/66265167_2532443040120888_3115339942444662784_o.jpg?_nc_cat=105&_nc_oc=AQnfIr255iuHGLsUGd-31kDYkKiJ-0KoAXX_fsaPPqt2315qivE4Ujku1_26uAiN_1U&_nc_ht=scontent-ort2-1.xx&oh=f6eef89a3794c3b8a40667c5493399aa&oe=5DB3BF25
It's not the correct email address.
The correct email address is in the links below:
https://www.otcmarkets.com/stock/WNTR/profile
https://backend.otcmarkets.com/otcapi/company/dns/news/document/36507/content
As a long term investor in this company, I'm loving the silence. This tells me that they are working diligently on the IND submission. Only issue a press release when it is material. EOM
Turnaround soon. Patients required here!
'concordia', the thing is, I've seen no "Name Drop" Pr's lately. I love the silence here.
'favorite', You are thinking as I, thinking the same with the silence. Personally I'm liking the silence here. Something serious is happening behind the scenes.
I see all the posts here on IH, about selling out because of the silence. I'm not even thinking about selling out here. The minute I would sell, news would come out. If I sold this now after holding this for over six years, I would sick to my stomach, if I sold it and a positive earth shattering press release came out.
Go PMCB
PharmaCyte will provide its shareholders with a link to the video interview next week.
https://ir.pharmacytebiotech.com/press-releases/detail/190
New WNTR website.
https://wdhinc.net/
Opportunity
This has created a buyer’s market for acquisitions of small and middle market companies. The current owners are taking money of the table for retirement, while continuing to manage the company for additional growth prospects. The companies can be acquired at 3 to 5 x EBIDTA.
There would be limited competition, as a publicly trading diversified holding company, that is focused on acquiring controlling stakes in companies with a transaction size of up to $10 million dollars.
The company is focused on using a public trading vehicle, to acquire ownership positions in small to middle market companies over the next three years.
The operations will provide for income from advisory services, interest, dividends and capital gains from investments in public and private companies in a variety of industries located worldwide.